New York (AFP) – A US review panel on Thursday recommended loosening restrictions on the much-hyped peptide BPC-157, voting that specialized pharmacies be allowed to produce it despite alarm bells from medical experts over safety concerns. The vote came as part of a two-day meeting by the panel tasked with considering whether seven total peptides should be added to the approved compounding list, which allows facilities to create custom drugs that will in turn be more accessible to the public.
Peptides are short chains of amino acids, which are the building blocks of proteins. They occur naturally in the body, but synthetic peptides are increasingly buzzy in the wellness industry, touted by influencers and celebrities as the key to an optimized life. Medical experts accused President Donald Trump’s health chief, Robert F. Kennedy Jr., of packing the Food and Drug Administration advisory committee with people who have strong ties to the peptide industry, given his personal interest in the products that he has said he has used to treat injuries.
The substances under review — including BPC-157, TB-500, and Semax — are among those that the administration of Trump’s predecessor, Joe Biden, restricted from compounding, notably over a lack of human clinical trial data. But that hasn’t thwarted use in many cases; substances can be purchased online from chemical suppliers “for lab use,” and are widely touted on social media among influencers, celebrities, and those inclined to follow “wellness” trends, like Kennedy.
The panel’s 8-6 vote, with one abstention, to recommend the FDA’s addition of BPC-157 to the bulks list is at odds with the expert opinions of career scientists at the agency. Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, told the committee she had voted no “because of the lack of efficacy data” and “safety concerns.” Member Brian Lee also voted no, saying: “I think this endorsement can be potentially harmful, and I cannot in good conscience vote yes.” But they were outnumbered by panelists who voted yes, with those members citing reasons including “the greater good” and “medical freedom” for their decisions.
The vote followed hours of presentations by FDA scientists who urged against recommending greater access to BPC-157, as well as public comment on both sides of the issue. Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official, urged against easing restrictions on the peptides. “This action is inconsistent with the FDA’s own standards for pharmacy compounding, poses dangers to consumers, and removes incentives for developing new pharmaceutical products through the standard drug approval process,” he said. He dubbed the burgeoning world of peptides as one of “pseudoscience and grift.”
Telehealth companies Hims & Hers were among those urging the panel to allow compounding the peptides, arguing that further restricting them will only drive Americans further into the gray market. Some peptides, like insulin or GLP-1, are well-studied and the risks and benefits of lab-created versions well-understood. But the synthetic peptides touted by influencers and biohackers, which are often injectable, are not. Such substances have not undergone the kind of large-scale trials the FDA would normally require to establish safety and efficacy.
The committee is due to consider six more peptides during the two-day meeting. The recommendations are not binding, but the FDA historically has given them significant weight.
© 2024 AFP
